entertainment -WSS

entertainment

author：fashion 2025-08-19 15:02:23 - browse：4987

Two $1 bills stapled together to make the shape of a heart against a red background. -- health policy coverage from STAT — Adobe

WASHINGTON — Doctors lowered the incidence of heart disease and strokes among their patients when Medicare rewarded them for focusing on sicker patients, according to research of a pilot program released Tuesday in the Journal of the American Medical Association. The pilot program didn’t increase overall costs at all.

The five-year pilot program is one of many that Medicare has run since the Affordable Care Act created an office to test whether Medicare payment policies can influence doctors in ways that keep patients healthier. That Obama-era initiative has not worked out as well as was hoped, but the Million Hearts Cardiovascular Disease Risk Reduction Model is one of the initiative’s bright spots.

Medicare paid doctors in the pilot program to assess the risk of heart problems, then Medicare paid them to focus on sicker patients. The pilot paid doctors more when they improved such measurements as blood pressure and cholesterol levels for sicker patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Do digital therapeutics have a future in medicine?

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

Cigna to pay $172 million to settle Medicare Advantage fraud probe

SAMSHA loosens regulations on methadone treatment centers

Inequities make cancer less preventable for women: report

Intercept Pharmaceuticals sells itself for less than $1 billion

How the Dana

focus

entertainment

Wikipedia

The high cost of giving birth even with insurance

Sudafed saga points to U.S. issues with evaluating older drugs

The cancer drug shortage isn’t new — and neither are the solutions

Woodcock on FDA’s accelerated approval and her next chapter

Apple is now the first public company to be valued at $3 trillion

Listen: Who gets the credit for GLP

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Vertex non

BioMarin wins approval for gene therapy to treat hemophilia A

Woodcock on FDA’s accelerated approval and her next chapter

hotspot

WHO recommends dropping component of many flu vaccines

Medicare drug price negotiation program allowed for now

What we need to know about Arena Bioworks

Vertex non

Sudafed saga points to U.S. issues with evaluating older drugs

Covid vaccines: Private market messier than government rollout

hotspot

entertainment

entertainment

focus